Patient portal
Leukaemia is the most common cancer in childhood. It occurs when white blood cells transform into malignant or cancerous cells.
Treatment of leukaemia in Spain
SJD Barcelona Children's Hospital belongs to Innovative Therapies for Children with Cancer (ITCC), which allows us to access the most innovative treatments and include our patients in pioneering clinical trials. An example of new treatments is the application of CAR-T 19 immunotherapy: we are one of the few pediatric centers in Europe and the only one in Spain that offers this therapy.
Currently, CAR-T 19 immunotherapy treatment is offered in patients who have undergone conventional treatments without success, usually with one or more relapses.
Why SJD Barcelona Children's Hospital?
The SJD Barcelona Children's Hospital's Oncology and Haematology Department is the national reference centre of for the treatment of developmental cancer and an international reference centre for determined types of tumours.
CAR-T ARI 0001 research
Outcomes
Acute lymphoblastic leukaemia patients, survival rate at five years
Research
The SJD Barcelona Children's Hospital investigates the main types of childhood leukaemia that affect our patients. The objective of our research groups on pediatric leukaemia is to deepen our knowledge of the origin and molecular basis of this type of cancer to achieve new tools for diagnosis, prognosis and treatment.
SJD Barcelona Children’s Hospital participates in a trial on a new therapy to treat lymphoblastic leukaemia
SJD Barcelona Children’s Hospital is participating in a trial to evaluate the safety and efficacy of a new CART-T therapy developed by Hospital Clínic to treat patients with lymphoma or acute lymphoblastic leukaemia (ALL) who do not respond to conventional treatments.
